Stuart Curry Dentistry Offers Metal-Free Fillings and Superior Preventive Care in Birmingham
Stuart Curry Dentistry continues to lead the way in preventive oral health with its commitment to providing metal-free dental fillings and comprehensive care for families throughout Birmingham and surrounding areas.
Stuart Curry Dentistry continues to lead the way in preventive oral health with its commitment to providing metal-free dental fillings and comprehensive care for families throughout Birmingham and surrounding areas. The practice offers cutting-edge, mercury-free restorations that blend seamlessly with natural teeth—prioritizing both aesthetics and long-term health.
As more patients seek safer and more attractive alternatives to traditional amalgam, the demand for Metal-Free Fillings in Birmingham has significantly increased. Stuart Curry Dentistry meets that need with durable, composite resin fillings designed to restore decayed or damaged teeth without the risks often associated with metal-based options.
'Patients are more informed today about what goes into their dental care,' said Dr. Stuart Curry, founder of Stuart Curry Dentistry. 'We're proud to offer solutions that not only look natural but also support whole-body health. Our metal-free fillings are part of a broader strategy to keep smiles strong, healthy, and beautiful for life.'
The practice also focuses heavily on preventive dentistry, helping patients avoid future complications through early detection, professional cleanings, and personalized oral health plans. Whether it's addressing early-stage cavities or providing routine exams, Stuart Curry Dentistry is known for delivering thoughtful, patient-centered care.
Those searching for Dental Fillings in Birmingham can rely on the clinic's commitment to quality and patient satisfaction. With a modern facility, advanced technology, and a highly trained team, the practice continues to raise the standard for general and cosmetic dental care in the region.
The clinic's holistic approach has earned it praise not only from local families but also from healthcare professionals throughout Alabama. As detailed in a recent piece by Stuart Curry Dentist, the practice has launched several initiatives aimed at improving Birmingham's overall dental health through education and accessible services.
Patients interested in Metal-Free Fillings in Birmingham or learning more about preventive care options can visit the practice's location at 4851 Cahaba River Rd, Ste 101 or contact the office directly to schedule a consultation.
Media Contact
Company Name: Stuart Curry Dentistry
Contact Person: Dr. Stuart Curry
Email: Send Email
Phone: 205-972-3831
Address: 4851 Cahaba River Rd. Ste 101
City: Birmingham
State: AL
Country: United States
Website: https://currydentistry.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
15 hours ago
- Globe and Mail
BioGrowing Shines at Probiota Americas 2025, Leading Innovation in Probiotic Applications for Oral and Weight Management
VANCOUVER - June 13, 2025 - BioGrowing, the Diamond Sponsor of Probiota Americas 2025, showcased groundbreaking advancements in oral health and weight management at the event. Through keynote presentations and panel discussions, the Chinese probiotic leader demonstrated its cutting-edge capabilities to the global scientific community. Innovative Oral Probiotic Solution Targets Billion-Dollar Market Dr. Zhanxi Hao, Vice President of the BioGrowing Research Institute, delivered a inspiring speech titled "Innovations In Oral Probiotics Research And Market Trends." He highlighted the rapid growth of the global oral healthcare market, projected to exceed $700 billion USD by 2030, with China's oral probiotic segment showing equally strong momentum. Probiotics, as core modulators of the oral microbiome, are driving oral health products to become a major market force due to their proven efficacy. As a pioneer in China's probiotic industry, BioGrowing has achieved technological leadership in oral probiotics through years of strain development: Lacticaseibacillus paracasei LPc-G110: The clinical research validating these oral probiotic strains was conducted at the Academic Centre for Dentistry Amsterdam (ACTA), ranked No. 1 in Europe and No. 2 globally in the QS World University Rankings for Dentistry. The trials demonstrated that BioGrowing's oral probiotic formulations effectively: Improve gingivitis, Reduce dental plaque formation, Decrease levels of harmful oral bacteria, Enhance oral micro-ecological stability. Ligilactobacillus salivarius LS-G60: Addresses halitosis at its source by inhibiting volatile sulfur compound (VSC) production. Clinically proven to outperform conventional treatments in combating halitosis. The Flora-Focus® Oral Health Fomula , developed based on these innovations, is now in industrial application. Concurrently launched, the novel OralBubble™ Probiotic Microbubble Lozenges deliver 10 Billion CFU per piece of clinically validated strains, offering a one-stop solution for 8 major oral concerns and meeting on-the-go oral health needs. Finished product testing confirms that the probiotic bubble tablets achieve VSC (volatile sulfur compound) inhibition rates of 98.76% at 16 hours and 98.09% at 24 hours post-administration, clinically validating their efficacy in delivering 24-hour oral freshness and halitosis reduction. Triple-Strain Consortium Addresses Global Obesity Challenge During the "Probiotics And Weight Management: Science or Myth?" roundtable discussion, BioGrowing's experts presented the company's latest research findings and scientific evidence supporting probiotic efficacy in weight management, exploring practical applications and potential in this field. Highlighting the public health crisis – global obesity rates surged from 36% (2000) towards 50% (2023) per the World Obesity Atlas 2025, with China designating 2025 as its "Weight Management Year" – BioGrowing introduced the Flora-Focus® Weight Management Fomula: Features a targeted triple-strain consortium: Lactobacillus gasseri LG-G12, Lactiplantibacillus plantarum ZJUF T17, and Lactiplantibacillus plantarum ZJUF T34. Mechanism: Enhances lipid metabolism efficiency, increases beige adipose tissue content, and inhibits high-fat diet-induced weight gain, while reducing hyperlipidemia risks associated with obesity. Provides a precise weight management solution for individuals with frequent dietary indiscretions, weight management goals, or dyslipidemia. Expanding Health Frontiers Through Scientific Rigor "From oral microbiome modulation to metabolic management, we are systematically building comprehensive probiotic health solutions," emphasized Dr. Hao. BioGrowing's relevant products have already secured international orders, marking the global reach of China's microbial technology innovation. Moving forward, BioGrowing remains committed to expanding health frontiers, delivering science-backed, safe, and effective health solutions to consumers worldwide. Media Contact Company Name: BIOGROWING CO.,LTD. Contact Person: Echo Sun Email: Send Email Country: China Website:
CTV News
a day ago
- CTV News
Period-tracking apps pose ‘significant risks' for users, new report finds
Experts say companies could sell the data of those who use menstrual cycle tracking apps. (Pexels) Menstrual cycle tracking apps could jeopardize the safety and privacy of users, a new report warns, with personal data commonly sold to companies. The stakes are high since period tracking apps have soared in popularity and become ubiquitous amid limited access to information, a lack of research and stigma about menstruation health. A 2024 study estimates that global downloads for the three most popular menstruation cycle tracking apps surpassed 250 million. Those who use apps that track periods often don't consider the data 'intimate' or commercially valuable, and need more protections from potential abuse of their personal information, according to the report released Tuesday by The Minderoo Centre for Technology and Democracy. MCTD is an independent team of academic researchers at the University of Cambridge in the U.K. 'Menstrual tracking applications turn personal health information into data points to be collected, analyzed, and sold,' according to the report. Data sold to companies, advertisers The study noted the apps pose 'significant risks' for users as femtech has become a 'lucrative trend' and the user data is 'extremely valuable' for a wide range of companies, from those that developed the app to big tech firms and advertising industries. Femtech refers to digital products, services or technologies promoting women's health and wellbeing, with period-tracking apps making up 50 per cent of the US$22 billion market in 2020. 'People vastly underestimate the commercial value of menstrual data and the extent to which it can provide insights into their political preferences, health issues, or reproductive choices,' researchers wrote. The apps offer a way for users to track daily information on anything related to their menstrual health, such as menstrual cycles, predictions on periods, premenstrual syndrome (PMS), ovulation and fertility. Security and privacy risks To add to the concerns, researchers say the apps also pose risks to data security and privacy, noting it's widely used in the online advertising industry. 'Self-tracking data has been used to police people's reproductive choices, to undermine a user's testimony in court, and it can lead to increased vulnerability in intimate relationships, partner violence, risks to job prospects via employer access to CTA (cycle tracking application) data, workplace monitoring, or possible health insurance discrimination,' according to the report. Meanwhile, the report also referred to 'severe security risks,' noting an example in the U.K. where period tracker data was used to charge women for illegally accessing abortion services. Are period apps accurate? The study notes many medical studies showed that the apps 'fail to accurately calculate cycle length or ovulation windows' and additional data from people is often not used to improve predictions. Rather, researchers say the information is 'predominantly a source of value' for the companies. 'With most apps providing no or very little information on how predictions are made, a 2023 study found that some users were encouraged to track more data to fine-tune their predictions and train an imagined algorithm,' it wrote. While users commonly turn to the apps to help them conceive or prevent getting pregnant, people with irregular cycles or conditions such as poly-cystic ovary syndrome, endometriosis, or premenstrual dysphoric disorder may also use the apps to try to understand their medical issues. Many people use the apps to track their emotions and bodily functions as well. Recommendations The report recommends improving health care for and incentivising research on menstrual and reproductive health, such as through cycle tracking companies and research institutes working together. It encourages schools and organizations to help raise awareness about menstrual tracking for all ages. Additionally, it recommends alternatives, such as public bodies developing apps that are 'trustworthy' and collect data in a 'responsible way.' The report also calls for stricter regulation of menstrual tracking data as 'sensitive health information' in the United States and tighter enforcement of existing regulations in the U.K. and European Union. It suggests improving security through 'consent options,' clear and accessible privacy policies, and prioritizing data privacy and security in the app design. Apps could be more 'transparent' by providing clear information on how tracking data is used to make predictions, with interface options for those who cannot or do not want to become pregnant. The report notes that not all women menstruate and not everyone with menstrual cycles is a woman. For instance, it wrote that children and teenagers have periods, trans men can menstruate and trans women can experience symptoms similar to premenstrual syndrome (PMS). Most apps are designed for straight cis women who want to get pregnant, it added. David Young, a privacy and regulatory law expert in Toronto, told in a video interview Monday that Canada's Personal Information Protection and Electronic Documents Act already follows the report's recommendations, though the law is 'not always enforced.' According to Canada's federal privacy law, an organization must not require individuals to consent to the collection, use or disclosure of their information beyond 'explicitly specified, and legitimate purposes.' 'Assuming those specific and legitimate purposes are the tracking that the individual is seeking by use of the app, then they shouldn't be allowed to also require, as a condition of using the app, that they're going to sell that information to somebody else,' Young said. He noted Canada also faces a problem with companies selling consumers' medical data, including electronic health records. Young said menstrual-related cycle data is considered 'sensitive personal health information.' 'And that has a very high standard of compliance under any privacy law, meaning that there must be clear ... consent to for whatever uses are going to be made of that information. So it's not something you can just use by way of implied consent.'
National Post
2 days ago
- National Post
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies
Article content CAMBRIDGE, England & SEATTLE — The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Article content Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Article content Article content Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Article content Garnett's research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capture hallmarks of patient tumors. The team will use vast numbers of these tumor organoids — mini tumors in a dish — as a model to better understand cancer mechanisms of plasticity and adaptability in response to treatments. Article content Theis' research team has been widely recognized for pioneering computational algorithms to solve complex biological challenges at the intersection of Artificial Intelligence and single cell genomics, in this context for in silico modeling of drug effects on cellular systems. The initiative will be run through Parse Biosciences' GigaLab, a state-of-the-art facility purpose built for the generation of massive scale single cell RNA sequencing datasets at unprecedented speed. Article content The Sanger, Helmholtz Munich, and Parse teams have developed automated methods to streamline laboratory procedures in addition to the computational methods required to analyze and discover insights within datasets of this size. Article content The ultimate aim of the collaboration is to build a single cell reference map that will enable virtual cell modeling and potentially help predict the effect of drugs in cancer patients – where resistance might develop, from which compounds, and where to target future treatment efforts. Article content Garnett, Group Leader at the Wellcome Sanger Institute and collaboration co-lead, said: 'We have developed a transformational platform to enable both large-scale organoid screening and the downstream data generation and analysis which has the potential to redefine our understanding of therapeutic responses in cancer. We aim to develop a community that brings the best expertise from academia and industry to progress the project. Studies of this magnitude are critical to the development of foundational models to better help us understand cancer progression and bring much needed advancement in the field.' Article content Theis, Director of the Computational Health Center at Helmholtz Munich and collaboration co-lead, said: 'Our vision of a virtual cell perturbation model is becoming increasingly feasible with recent advances in AI — but to scale effectively, we need large, high-quality single cell perturbation datasets. This collaboration enables that scale, and I'm excited to move toward AI-driven experimental design in drug discovery.' Article content Dr. Charlie Roco, Chief Technology Officer at Parse Biosciences, said: 'We are incredibly excited to bring the power of GigaLab to visionary partners. Leveraging Parse's Evercode chemistry, the GigaLab can rapidly produce large single cell datasets with exceptional quality. Combining the expertise of the Wellcome Sanger Institute and Helmholtz Munich with the speed and scale achieved by the GigaLab enable the opportunity to fundamentally change our understanding of cancer.' Article content About Parse Biosciences Article content Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Article content With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by over 2,500 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™. Article content Parse Biosciences is based in Seattle's vibrant South Lake Union district, where it recently expanded into a new headquarters and state-of-the-art laboratory. To learn more, please visit Article content About Helmholtz Munich Article content Helmholtz Munich is a leading biomedical research center. Its mission is to develop breakthrough solutions for better health in a rapidly changing world. Interdisciplinary research teams focus on environmentally triggered diseases, especially the therapy and prevention of diabetes, obesity, allergies, and chronic lung diseases. With the power of artificial intelligence and bioengineering, researchers accelerate the translation to patients. Helmholtz Munich has around 2,500 employees and is headquartered in Munich/Neuherberg. It is a member of the Helmholtz Association, with more than 43,000 employees and 18 research centers the largest scientific organization in Germany. More about Helmholtz Munich (Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH): About the Wellcome Sanger Institute The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast – we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at or follow us on Twitter, Facebook, LinkedIn and on our Blog. Article content Article content Article content
